Document is current
Any future updates will be listed below
-
Authors
Chapman, Kenneth
van Zyl-Smit, Richard
Maspero, Jorge
Kerstjens, Huib A M
Gon, Yasuhiro
Hosoe, Motoi
Tanase, Ana-Maria
Pethe, Abhijit
Shu, Xu
D’Andrea, Peter https://orcid.org/0000-0001-9831-1568
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02554786 at ClinicalTrials.govnct02571777 at ClinicalTrials.govDocuments that mention this clinical trial
P224 Efficacy and long-term safety of QMF149 (indacaterol acetate/mometasone furoate) versus mometasone furoate and versus salmeterol xinafoate/fluticasone propionate in patients with inadequately-controlled asthma: The PALLADIUM study
https://doi.org/10.1136/thorax-2019-btsabstracts2019.367
One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies
https://doi.org/10.1136/bmjresp-2020-000819
nct02554786 at ClinicalTrials.govDocuments that mention this clinical trial
Triple Therapy with Mometasone/Indacaterol/Glycopyrronium or Doubling the ICS/LABA Dose in GINA Step 4: IRIDIUM Analyses
https://doi.org/10.1007/s41030-023-00234-y
One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies
https://doi.org/10.1136/bmjresp-2020-000819
Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population
https://doi.org/10.1136/bmjresp-2020-000856
nct02571777 at ClinicalTrials.govDocuments that mention this clinical trial
P224 Efficacy and long-term safety of QMF149 (indacaterol acetate/mometasone furoate) versus mometasone furoate and versus salmeterol xinafoate/fluticasone propionate in patients with inadequately-controlled asthma: The PALLADIUM study
https://doi.org/10.1136/thorax-2019-btsabstracts2019.367
One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies
https://doi.org/10.1136/bmjresp-2020-000819
Documents that mention this clinical trial
Triple Therapy with Mometasone/Indacaterol/Glycopyrronium or Doubling the ICS/LABA Dose in GINA Step 4: IRIDIUM Analyses
https://doi.org/10.1007/s41030-023-00234-y
One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies
https://doi.org/10.1136/bmjresp-2020-000819
Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population
https://doi.org/10.1136/bmjresp-2020-000856
-
Funding
Funding for this research was provided by:
Novartis Pharma (Not applicable)
- License Information
